Insider Selling: ClearPoint Neuro (NASDAQ:CLPT) Director Sells 5,415 Shares of Stock

ClearPoint Neuro, Inc. (NASDAQ:CLPT) Director Timothy Richards sold 5,415 shares of the business’s stock in a transaction that occurred on Monday, June 1st. The stock was sold at an average price of $12.17, for a total transaction of $65,900.55. Following the completion of the transaction, the director owned 87,198 shares of the company’s stock, valued at approximately $1,061,199.66. The trade was a 5.85% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

ClearPoint Neuro Stock Down 2.2%

NASDAQ CLPT traded down $0.28 during mid-day trading on Tuesday, reaching $12.36. The stock had a trading volume of 517,115 shares, compared to its average volume of 607,316. ClearPoint Neuro, Inc. has a 1 year low of $8.27 and a 1 year high of $30.10. The stock has a market cap of $370.68 million, a PE ratio of -12.31 and a beta of 1.31. The company has a fifty day moving average price of $10.73 and a 200 day moving average price of $12.54. The company has a debt-to-equity ratio of 2.63, a current ratio of 5.79 and a quick ratio of 4.88.

ClearPoint Neuro (NASDAQ:CLPT) last announced its quarterly earnings data on Wednesday, May 13th. The company reported ($0.32) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.28) by ($0.04). ClearPoint Neuro had a negative return on equity of 140.96% and a negative net margin of 71.57%.The firm had revenue of $12.13 million during the quarter, compared to analysts’ expectations of $11.97 million. On average, research analysts expect that ClearPoint Neuro, Inc. will post -1.05 earnings per share for the current year.

Institutional Investors Weigh In On ClearPoint Neuro

Large investors have recently added to or reduced their stakes in the stock. Caitong International Asset Management Co. Ltd bought a new stake in ClearPoint Neuro in the 4th quarter worth approximately $25,000. BNP Paribas Financial Markets grew its position in ClearPoint Neuro by 2,435.2% in the 2nd quarter. BNP Paribas Financial Markets now owns 2,231 shares of the company’s stock worth $27,000 after purchasing an additional 2,143 shares during the period. Legal & General Group Plc bought a new stake in shares of ClearPoint Neuro during the 2nd quarter valued at $35,000. Huntington National Bank bought a new stake in shares of ClearPoint Neuro during the 3rd quarter valued at $44,000. Finally, Russell Investments Group Ltd. grew its position in shares of ClearPoint Neuro by 1,079.0% during the 3rd quarter. Russell Investments Group Ltd. now owns 2,358 shares of the company’s stock valued at $51,000 after acquiring an additional 2,158 shares during the period. Institutional investors own 30.08% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts recently weighed in on CLPT shares. B. Riley Financial boosted their price objective on shares of ClearPoint Neuro from $18.00 to $20.00 and gave the stock a “buy” rating in a report on Wednesday, March 18th. Stifel Nicolaus started coverage on shares of ClearPoint Neuro in a report on Friday, May 8th. They issued a “buy” rating and a $16.00 price objective for the company. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of ClearPoint Neuro in a research report on Monday, April 20th. Two equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average target price of $18.00.

About ClearPoint Neuro

ClearPoint Neuro, Inc is a medical technology company specializing in the development and commercialization of an MRI-guided therapy platform for minimally invasive neurosurgical procedures. Headquartered in Cambridge, Massachusetts, the company’s flagship ClearPoint® SmartFrame™ system enables surgeons to perform accurate and efficient intracranial interventions by providing real-time magnetic resonance imaging feedback. This technology is designed to improve patient safety and outcomes in treatments ranging from deep brain stimulation electrode placement to laser ablation of epileptic foci and brain tumors.

The ClearPoint System integrates hardware, software and imaging capabilities to guide instruments through the brain with submillimeter precision.